•
Dec 31, 2022

Ultralife Q4 2022 Earnings Report

Reported operating profit and adjusted EBITDA on revenue increase, driven by government/defense and commercial sales growth.

Key Takeaways

Ultralife Corporation reported a significant increase in revenue and a favorable swing in operating profit for Q4 2022 compared to Q4 2021. Revenue increased by 51.9%, driven by growth in both government/defense and commercial sales. The company's backlog reached a record high, and gross margin improved compared to the previous quarter.

Revenue increased by 51.9% to $36.1 million, driven by growth in government/defense and commercial sales.

Gross margin improved by 220 basis points over the third quarter due to price realization.

Operating profit was $0.2 million, a $2.2 million favorable swing year-over-year, excluding a one-time severance charge.

Backlog increased to $111 million, the highest level in the company's history.

Total Revenue
$36.1M
Previous year: $23.8M
+51.9%
EPS
-$0.01
Previous year: -$0.09
-88.9%
Adjusted EBITDA
$2M
Gross Profit
$8.1M
Previous year: $5.3M
+52.8%
Cash and Equivalents
$5.63M
Previous year: $8.33M
-32.4%
Free Cash Flow
$2.28M
Previous year: -$4.63M
-149.3%
Total Assets
$168M
Previous year: $160M
+5.6%

Ultralife

Ultralife

Forward Guidance

Ultralife Corporation is focused on recapturing gross margin and driving profitable growth in 2023.

Positive Outlook

  • Continued execution of price realization activities
  • Qualification of alternate component suppliers
  • Lean manufacturing initiatives
  • Strengthening relationships with key customers
  • Utilizing global new product development and sales resources

Challenges Ahead

  • Uncertain availability of components in the supply chain
  • Component cost inflation
  • Prolonged lead times and logistics delays
  • Potential reductions in revenues from key customers
  • Uncertain global economic conditions